<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667574</url>
  </required_header>
  <id_info>
    <org_study_id>2013_36</org_study_id>
    <secondary_id>2013-004338-13</secondary_id>
    <nct_id>NCT02667574</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)</brief_title>
  <acronym>VISMONEO</acronym>
  <official_title>Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, non-comparative, multicenter, phase II study of Vismodegib in patients with&#xD;
      locally advanced BCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of&#xD;
      150 mg (in accordance with the product SmPC) per administration. One cycle of therapy will be&#xD;
      defined as 28 days of treatment. The treatment will be renewed once a month depending on the&#xD;
      product tolerance.&#xD;
&#xD;
      The trial will consist of a Screening Period (Day -28 to -1), a Treatment Period (Day 1 to&#xD;
      BOR), one End of Treatment Visit, one Surgery Visit and 8 Safety Follow-Up Visits after the&#xD;
      last dose of Vismodegib (+/- 5 days). Day 1 of the study will be defined as the first day a&#xD;
      patient receives Vismodegib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 18, 2014</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in surgery stages</measure>
    <time_frame>Between baseline and maximum 10 months of treatment</time_frame>
    <description>comparison of the surgery stages before and after the treatment with Vismodegib according to specific surgery stage table</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with locally advanced BCC with down-staging of surgical procedures with Vismodegib</measure>
    <time_frame>from 4 to 10 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gravity index related to the surgical or functional results (global score)</measure>
    <time_frame>At maximum 10 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of the clinical benefits at BOR</measure>
    <time_frame>At maximum 10 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of treatment toxicity according to NCI-CTC, v4.0</measure>
    <time_frame>2 months after the surgery and maximum 12 months after the Vismodegib initiation</time_frame>
    <description>National Cancer Institute - CommonToxicity Criteria (NCT-CTC) for the recognition and grading severity of adverse effects of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment by Skindex-16 questionnaire</measure>
    <time_frame>At screening, at 3 months, at 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the tumor recurrence rate</measure>
    <time_frame>at 3 years of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the cytological response by biopsy</measure>
    <time_frame>from 4 to 10 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>open-label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERIVEDGE</intervention_name>
    <arm_group_label>open-label</arm_group_label>
    <other_name>VISMODEGIB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with BCC, which surgery stage is A, B or C (cf. Appendix 3: Definition of&#xD;
             surgery stages), with a diameter ≥ 3cm in zones at intermediate risk of tumor&#xD;
             recurrence and a BCC with a diameter of ≥ 2 cm in the zones at higher risk of tumor&#xD;
             recurrence. According to the HAS recommendations, two zones are taken into&#xD;
             consideration:&#xD;
&#xD;
               -  Zones at intermediate risk of tumor recurrence: forehead, cheek, chin, neck and&#xD;
                  scalp&#xD;
&#xD;
               -  Zones at higher risk of tumor recurrence: nose and periorificial sites of the&#xD;
                  cephalic extremity&#xD;
&#xD;
          2. The decision to include the patient in this study should be taken during the&#xD;
             Pluridisciplinary Committee Meeting (RCP). During this RCP, the radiotherapy should be&#xD;
             considered as an inadequate treatment. (If the radiotherapist is absent during the&#xD;
             meeting, his opinion should be documented in the patient's medical record).&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
          4. Age ≥ 18 years old&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0, 1, or 2&#xD;
&#xD;
          6. At least one histologically confirmed lesion...&#xD;
&#xD;
          7. Patients with Gorlin syndrome may enroll in this study but must meet the other&#xD;
             inclusion criteria&#xD;
&#xD;
          8. Patients with measurable and/or non-measurable disease (as defined by RECIST, v1.1)&#xD;
&#xD;
          9. Adequate organ function, as evidenced by the following laboratory results:&#xD;
&#xD;
               -  Hemoglobin &gt; 8.5 g/dL&#xD;
&#xD;
               -  Granulocyte count ≥ 1000/μL&#xD;
&#xD;
               -  Platelet count ≥ 75,000/μL&#xD;
&#xD;
               -  Aspartate transaminase (AST ) and alanine transaminase (ALT) ≤ 3 × upper limit of&#xD;
                  normal (ULN)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × ULN or within 3 × ULN for patients with documented&#xD;
                  Gilbert syndrome&#xD;
&#xD;
         10. Negative serum pregnancy test within 7 days prior to commencement of dosing in&#xD;
             premenopausal women. Women of non-childbearing potential may be included if they are&#xD;
             either surgically sterile or have been postmenopausal for ≥ 1 year.&#xD;
&#xD;
         11. Women of childbearing potential must use one highly-effective method of contraception&#xD;
             and one barrier method of contraception during treatment and for 24 months after the&#xD;
             final dose. Highly-effective methods of contraception are defined as those which&#xD;
             result in a low failure rate (i.e., less than 1% per year) when used consistently and&#xD;
             correctly (e.g., implants, injectables, or intra-uterine devices; refer to Appendix 8&#xD;
             for more details). At the discretion of the Investigator, acceptable methods of&#xD;
             contraception may include total abstinence. (Periodic abstinence [e.g., calendar,&#xD;
             ovulation, symptothermal, and postovulation methods] and withdrawal are not acceptable&#xD;
             methods of contraception.).&#xD;
&#xD;
         12. For male patients with female partners of childbearing potential, agreement top use a&#xD;
             condom with spermicide, even after vasectomy, during sexual intercourse with partners&#xD;
             while being treated with Vismodegib and for two months after completion of study&#xD;
             treatment&#xD;
&#xD;
         13. For male patients, agreement not to donate semen during the study and for 24 months&#xD;
             after discontinuation of Vismodegib&#xD;
&#xD;
         14. Agreement not to donate blood or blood products during the study and for at least 24&#xD;
             months after discontinuation of Vismodegib.&#xD;
&#xD;
         15. Life expectancy &gt; 12 weeks&#xD;
&#xD;
         16. Patients covered by a Health Insurance System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability or unwillingness to swallow capsules&#xD;
&#xD;
          2. Patients with BCC situated out of the head or the neck area&#xD;
&#xD;
          3. Pregnancy or lactation&#xD;
&#xD;
          4. Concurrent non-protocol-specified anti-tumor therapy (e.g., chemotherapy, other&#xD;
             targeted therapy or photodynamic therapy&#xD;
&#xD;
          5. Chemotherapy within 4 weeks prior to enrollment&#xD;
&#xD;
          6. Participation in another clinical trial within 4 weeks prior to enrollment&#xD;
&#xD;
          7. Radiotherapy within 6 months prior to enrolment&#xD;
&#xD;
          8. Metastatic BCC&#xD;
&#xD;
          9. Uncontrolled medical illnesses such as infection requiring treatment with intravenous&#xD;
             antibiotics.&#xD;
&#xD;
         10. History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates use of an investigational drug or that might affect interpretation of&#xD;
             the results of the study or that renders the patient at high risk from treatment&#xD;
             complications.&#xD;
&#xD;
         11. Patients with a rare hereditary problem of galactose intolerance, primary hypolactasia&#xD;
             or glucose-galactose malabsorption (according to the product SmPC).&#xD;
&#xD;
         12. Patients unable or unwilling to comply with the protocol requirements&#xD;
&#xD;
         13. Patients in emergency situations&#xD;
&#xD;
         14. Patients kept in detention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent MORTIER, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Boulogne sur mer</name>
      <address>
        <city>Boulogne sur mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Dermatologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Paris</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>basal cell carcinoma</keyword>
  <keyword>surgery</keyword>
  <keyword>stage</keyword>
  <keyword>vismodegib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

